The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma
Multiple myeloma accounts for 1% of all new cancers worldwide. It is the second most common haematological malignancy and has a low five-year survival rate (53.2%). Myeloma remains an incurable disease and is caused by the growth of malignant plasma cells in the bone marrow. Current anti-myeloma the...
Guardado en:
Autores principales: | Georgia Stewart, Andrew Chantry, Michelle Lawson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/18bb1f7449264767a940c631278022a6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress
por: Jinqiong Jiang, et al.
Publicado: (2021) -
The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
por: Kyle M. Pierce, et al.
Publicado: (2021) -
Mechanisms of Cell Entry by dsRNA Viruses: Insights for Efficient Delivery of dsRNA and Tools for Improved RNAi-Based Pest Control
por: Luc Swevers, et al.
Publicado: (2021) -
Oncolytic Virotherapy
Publicado: (2016) -
Native and non-indigenous boring polychaetes in Chile: a threat to native and commercial mollusc species
por: MORENO,RODRIGO A, et al.
Publicado: (2006)